摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether | 148081-69-0

中文名称
——
中文别名
——
英文名称
Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether
英文别名
3-Hydroxy-6-butyloxy-1.2.4-trimethyl-benzol;4-Butyloxy-2.3.6-trimethyl-phenol;4-Butoxy-2,3,6-trimethyl-phenol;Phenol, 4-butoxy-2,3,6-trimethyl-;4-butoxy-2,3,6-trimethylphenol
Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether化学式
CAS
148081-69-0
化学式
C13H20O2
mdl
——
分子量
208.301
InChiKey
MYRYIFIFOOHOBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    327.7±37.0 °C(Predicted)
  • 密度:
    0.990±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aethersodium methylate四氯化锡 作用下, 以 为溶剂, 生成 (2R,3S,4S,5S,6R)-2-(4-butoxy-2,3,6-trimethylphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
    参考文献:
    名称:
    Inhibitory Effects of (4-Alkoxy-2,3,6-trimethylphenyl)glycopyranosides on Histamine Release Induced by Antigen-Antibody Reaction.
    摘要:
    检测了新合成的4-烷氧基-2,3,6-三甲基苯基D-吡喃糖苷对由抗原-抗体反应引起的组胺释放的抑制作用。在测试的化合物中,4-己氧基-2,3,6-三甲基苯基α-D-甘露糖吡喃糖苷表现出最强的抑制作用。此外,4-己氧基-2,3,6-三甲基苯基α-D-吡喃葡糖苷和α-D-吡喃半乳糖苷显著抑制抗原诱导的组胺释放,且它们的活性强于相应的β-异构体。这些结果表明这些化合物可能具有优秀的抗过敏活性。
    DOI:
    10.1248/cpb.42.1002
  • 作为产物:
    描述:
    三甲基氢醌正丁醇 在 phosphomolybdic acid 作用下, 反应 6.0h, 以73%的产率得到Butyl-(4-hydroxy-2.3.5-trimethyl-phenyl)-aether
    参考文献:
    名称:
    Synthesis of 4-Alkoxyaryl .BETA.-D-Glucopyranosides and Their Inhibitory Effects on Histamine Release from Rat Peritoneal Mast Cells Induced by Concanavalin A.
    摘要:
    研究了新合成的4-烷氧基苯基β-D-葡萄糖苷对刀豆球蛋白A诱导的大鼠腹腔肥大细胞组胺释放的抑制作用。将疏水性(k')与化合物的抑制活性作图,显示出明显的最大值,其中4-癸氧基-2,3,6-三甲基苯基β-D-葡萄糖苷在测试的化合物中是最有效的抑制剂。
    DOI:
    10.1248/cpb.42.570
点击查看最新优质反应信息

文献信息

  • Synthesis and Anti Lipid-Peroxidation Activity of Hydroquinone Monoalkyl Ethers.
    作者:Yasunori NIHRO、Haruhiro FURUKAWA、Satoshi SOGAWA、Tzer Chuan WANG、Hideki MIYATAKA、Hitoshi MATSUMOTO、Tokutaro MIKI、Toshio SATOH
    DOI:10.1248/cpb.42.576
    日期:——
    series of hydroquinone monoalkyl ethers was synthesized and evaluated for anti lipid-peroxidation activity in rat liver microsomes. 4-Hexyloxy-2,3,6-trimethylphenol (9), having a low redox potential, as well as ascorbic acid exhibited the strongest anti lipid-peroxidation activity (IC50 = 4.2 x 10(-7) M). Structure-activity relationship studies demonstrated that the inhibitory effect of hydroquinone monoalkyl
    合成了一系列氢醌单烷基醚,并评估了其在大鼠肝微粒体中的抗脂质过氧化活性。氧化还原电位低的4-己氧基-2,3,6-三甲基苯酚(9)以及抗坏血酸表现出最强的抗脂质过氧化活性(IC50 = 4.2 x 10(-7)M)。结构活性关系研究表明,对苯二酚单烷基醚对脂质过氧化的抑制作用通过获得最佳疏水性而增加,而由于疏水性不足或过度而降低。
  • Synthesis of 4-Alkoxyaryl .BETA.-D-Glucopyranosides and Their Inhibitory Effects on Histamine Release from Rat Peritoneal Mast Cells Induced by Concanavalin A.
    作者:Tzer Chuan WANG、Haruhiro FURUKAWA、Yasunori NIHRO、Hisao KAKEGAWA、Hitoshi MATSUMOTO、Toshio SATOH
    DOI:10.1248/cpb.42.570
    日期:——
    The inhibitory effects of newly synthesized 4-alkoxyaryl β-D-glucopyranosides on histamine release from rat peritoneal mast cells induced by concanavalin A were examined. A plot of hydrophobicity (k') against inhibitory activity of the compounds showed a distinct maximum, and 4-decyloxy-2, 3, 6-trimethylphenyl β-D-glucopyranoside was the most potent inhibitor among the tested compounds.
    研究了新合成的4-烷氧基苯基β-D-葡萄糖苷对刀豆球蛋白A诱导的大鼠腹腔肥大细胞组胺释放的抑制作用。将疏水性(k')与化合物的抑制活性作图,显示出明显的最大值,其中4-癸氧基-2,3,6-三甲基苯基β-D-葡萄糖苷在测试的化合物中是最有效的抑制剂。
  • Curative drug for neurodegenerative diseases
    申请人:NIPPON HYPOX LABORATORIES INCORPORATED
    公开号:EP2052719A1
    公开(公告)日:2009-04-29
    A compound is prepared based on Formula 1: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms. The diseases include Alzheimer's and Parkinson's disease.
    根据式 1 制备化合物: 其中,R1 代表碳原子数为 4 至 8 的烷基,R2 代表氢原子、碳原子数为 2 至 6 的烷基羰基或碳原子数为 2 至 6 的烷氧羰基。治疗神经退行性疾病的药物可主要由该化合物或由其环糊精包合物组成的氢醌衍生物制备。这种治疗神经退行性疾病的药物具有安全有益的效果,可抑制氧化应激导致的神经细胞紊乱,从而阻止症状的发展。这些疾病包括阿尔茨海默病和帕金森病。
  • Hepatic Fibrosis Inhibitor
    申请人:NIPPON HYPOX LABORATORIES INCORPORATED
    公开号:EP2110127A1
    公开(公告)日:2009-10-21
    The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.
    含有由以下化学式表示的化合物的肝纤维化抑制剂可抑制由慢性肝炎等各种肝病和肝损伤引起的肝纤维化和肝硬化的进展: 其中,R1 代表碳数为 4 至 8 的烷基,R2 代表氢原子、碳数为 2 至 6 的烷基羰基或碳数为 2 至 6 的烷氧羰基。
  • CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION
    申请人:NIPPON HYPOX LABORATORIES INCORPORATED
    公开号:EP3287128A1
    公开(公告)日:2018-02-28
    A novel agent which is effective in the prevention or treatment of a chronic respiratory disease such as COPD, interstitial pneumonia and asthma is provided. The therapeutic agent for a chronic respiratory disease comprises, as an active ingredient, a hydroquinone derivative represented by general formula (1) wherein R1 represents an alkyl group having 4 to 8 carbon atoms, and R2 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an alkoxycarbonyl group having 2 to 6 carbon atoms.
    本发明提供了一种新型制剂,可有效预防或治疗慢性阻塞性肺病、间质性肺炎和哮喘等慢性呼吸道疾病。该慢性呼吸道疾病治疗剂包括通式(1)代表的氢醌衍生物作为活性成分,其中 R1 代表具有 4 至 8 个碳原子的烷基,R2 代表氢原子、具有 2 至 6 个碳原子的烷基羰基或具有 2 至 6 个碳原子的烷氧基羰基。
查看更多